Rani Therapeutics is developing a novel technology platform to convert injectable drugs such as TNFα inhibitors, interleukin antibodies, basal insulin and GLP-1 into oral pills. Rani currently has pharmaceutical collaborations with Novartis and Astra Zeneca.
Rani entered into a collaboration with Novartis to evaluate Rani's novel oral biotherapeutics drug delivery platform in mid-2015.
Rani entered into a collaboration with MedImmune to evaluate Rani's novel oral drug delivery platform in the Metabolic Disease field in early 2016. MedImmune is the global biologics research and development arm of AstraZeneca.
MedImmune has a growing portfolio of innovative biologics in the area of cardiovascular/metabolic disease, which is an important therapeutic area for AstraZeneca and MedImmune. Success in this program coupled with Rani's technology could represent an innovative solution for delivering biologics orally to metabolic disease patients.